Monte Rosa Therapeutics: T. Rowe Price reports 8.6% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Monte Rosa Therapeutics, Inc. was the subject of Amendment No. 8, in which T. Rowe Price Associates, Inc. reported 7,356,865 common shares, or 8.6% of the class, as beneficially owned. T. Rowe Price reported sole voting power over 7,349,108 shares and sole dispositive power over 7,356,865 shares, while expressly denying that the report was an admission that it is the beneficial owner. Vice President Ellen York signed the statement.
Key Figures
Key Terms
beneficial ownership regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.